Clinical Trials Logo

Adverse Effect clinical trials

View clinical trials related to Adverse Effect.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT05743985 Active, not recruiting - Clinical trials for Inflammatory Response

Efficacy and Safety of Hemp-derived, Full Spectrum Cannabigerol (CBG) in Adults

Start date: August 1, 2022
Phase: N/A
Study type: Interventional

The goal of this observational study is to provide exploratory research into the in vivo physiological and psychological effects, if any, of cannabigerol (CBG) in healthy human adults age 21 or over. The main questions it aims to answer are: - What effect, if any, does daily oral consumption of 50mg of full spectrum CBG have on the mental, physical, and emotional wellbeing of healthy individuals, as measured by self-report Medical Symptom Questionnaire and 36-Item Short Form Health Survey scores? - Is CBG effective at reducing inflammation in the body, as measured by HSCRP, ESR, and PSA inflammatory markers? - Do age, gender, weight, or state of body inflammation have an effect on the perceived efficacy of CBG? - What adverse effects, if any, are associated with CBG use? Over the course of the 12-week study, participants will: - Take baseline MSQ and SF-36 surveys, as well as a clinical visit with blood draws for HSCRP, ESR, and PSA testing - Consume one (1) 50mg capsule of full spectrum CBG daily by mouth with food for 8 weeks, followed by a 4-week washout period - Complete biweekly SF-36 surveys as well as MSQ surveys every 4 weeks - Attend a clinical visit every 4 weeks for clinical observation and blood draws for HSCRP, ESR, and PSA (male subjects)

NCT ID: NCT03889314 Active, not recruiting - Clinical trials for Cardiovascular Diseases

The DEtermining Statin Intolerance FOr Rosuvastatin (DESIFOR) Trial

DESIFOR
Start date: April 26, 2019
Phase: Phase 4
Study type: Interventional

This study will enroll patients who previously were not able to tolerate being on a statin medication due to muscle-related side effects. Research has shown that many people who have muscle symptoms on statin therapy do not experience the same side effects if they try it again later. This study is part of a larger effort to: - See how common it is for patients to still be intolerant of statin medication after trying it a second time; and - For those patients who do tolerate being on a statin after trying it a second time, see how common it is for them to still be taking the statin 3 months after completing the main part of the study. Patients who agree to participate will be given a 5 month randomly allocated supply of statin and placebo and track their symptoms weekly.